From the 1Programa de Pós-Graduação em Ciência Cíncica Interdisciplinar e 2Grupo de Apoio ao Adolescente e à Criança Com Câncer - Graacc, Serviço de Oncologia, Universidade Federal de São Paulo – UNIFESP (Postgraduate Program in Interdisciplinary Surgical Science and Pediatric Oncology Institute – Support Group for Adolescent and Child with Cancer (IOP-GRAACC) - Federal University of São Paulo – UNIFESP), São Paulo, SP, Brazil.

ABSTRACT - Background: The treatment of neuroblastoma is dependent on exquisite staging; is performed postoperatively and is dependent on the surgeon’s expertise. The use of risk factors through imaging on diagnosis appears as predictive of resectability, complications and homogeneity in staging. Aim: To evaluate the traditional resectability criteria with the risk factors for resectability, through the radiological images, in two moments: on diagnosis and in pre-surgical phase. Were analyzed the resectability, surgical complications and relapse rate. Methods: Retrospective study of 27 children with abdominal and pelvic neuroblastoma stage 3 and 4, with tomography and/or resonance on the diagnosis and pre-surgical, identifying the presence of risk factors. Results: The mean age of the children was 2.5 years at diagnosis, where 55.6% were older than 18 months, 51.9% were girls and 66.7% were in stage 4. There was concordance on resectability of the tumor by both methods (INSS and IDRFs) at both moments of the evaluation, at diagnosis (p=0.007) and post-chemotherapy (p=0.019); In this way, all resectable patients by IDRFs in the post-chemotherapy had complete resection, and the unresectable ones, 87.5% incomplete. There was remission in 77.8%, 18.5% relapsed and 33.3% died. Conclusions: Resectability was similar in both methods at both pre-surgical and preparative chemotherapy; preoperative chemotherapy increased resectability and decreased number of risk factors, where the presence of at least one IDRF was associated with incomplete resections and surgical complications; relapses were irrelevant.

INTRODUCTION

Neuroblastic tumors were described by Wright in 1910 and originate from indifferentiated nervous cells from the neural crest, present at the adrenal medulla, sympathetic ganglia and plexus. For this reason, they can grow in various parts of the body, being 48% adrenal, 25% retroperitoneal, 16% thoracic and are rarer on the neck and pelvis\textsuperscript{1,2,3,11,17}. The etiology of neuroblastoma is unknown, but it seems to be related to congenital and genetic anomalies\textsuperscript{4,7,10}. Neuroblastoma is the most common extracranial solid tumor in children and represents 10% of childhood cancers (one case for each 7000 children born) and
15% of pediatric cancer deaths. In São Paulo State, Brazil, it represents 7.7 cases per million children. 30% have until one year of age and 90% aged until 19 months. They are heterogeneous tumors that can mature spontaneously or be highly undifferentiated, depending on the biology of the tumor. Thus, biological and molecular factors are related to clinical presentation and prognosis. Signs and symptoms depend on tumor site, but these tumors involve the main vascular trunks of the body and are often metastatic at diagnosis. Surgical resection can be very challenging and severe complications may occur, although complete resection is the aim of the surgery. On the other hand, complete resection is often related to favorable histology. Clinical symptoms may also be related to catecolamines and VIP produced by the tumor. Image studies are essential for staging and determination of the primary tumor site and diagnosis is made through tumor biopsy or bone marrow infiltration of neuroblasts.

Staging determine risk groups and individual treatment and several systems were proposed. In 1988, INSS (International Neuroblastoma Staging System) was presented as a common language for neuroblastoma staging, but it is made postoperatively and dependent on surgical expertise. So, in 2009 the International Neuroblastoma Risk Group (INRG) established a new staging system: INRGSS – International Neuroblastoma Risk Group Staging System, that evaluates the initial images at diagnosis and describes more than 20 risk factors, the IDRFS – Image-Defined Risk Factors, that predicts surgical risks and challenges for complete resection at diagnosis.

The presence of IDRFS is related to surgical complications and incomplete resections and literature uses this in order to equalize the type of resections among different institutions in the world.

The aim of this study was to compare the traditional resectability criteria (INSS) with the image risk factors criteria (IDRF) for resectability, in two moments: at diagnosis and preoperatively after chemotherapy in a reference institution for pediatric cancer in Brazil.

METHOD

This is a retrospective review of patients with neuroblastoma treated at the Pediatric Oncology Institute – GRAACC – UNIFESP from 2000 to 2015. Inclusion criteria were: patients with abdominal and pelvic neuroblastomas stages 3 and 4 that had images at diagnosis and before surgery. From 198 patients treated for neuroblastic tumors in the observation period, 64 met the inclusion criteria, but 25 were excluded because images could not be found, nine were referred to the institution after surgery elsewhere and three were initially diagnosed as renal tumors. Thus 27 patients were included in the study and clinical data were collected. Images at diagnosis and post-chemotherapy before surgery were reviewed by surgeons and radiologists. The aim was to evaluate resectability at diagnosis and after chemotherapy based on the presence of IDRFS described by Brisse et al. (2009) as part of the INRGSS staging system and to determine if the system would impact the surgical decision made for each patient using INSS.

Statistical analysis

SPSS 20.0 and STATA 12 were used; 5% significance was considered. Kappa and McNemar coefficients were used to compare resectability at diagnosis and post-chemotherapy between INSS and IDRFS systems. Uni and multivariate analysis Kaplan-Meier curves and Cox regression models were done.

RESULTS

Data from 27 children were analyzed. Age varied from 0-9 years, mean 2.5 years, median two years. Mean time from beginning of symptoms and diagnosis was 1.4 year; 51.9% were females; 55.6% were aged more than 18 months at diagnosis; 66.7% were stage 4, and it was also verified, similar participations by location of the tumor (p=0.895, Table 1)

TABLE 1 – Patients characteristics

| n | % |
|---|---|
| Gender | 27 | 100.0 |
| Female | 14 | 51.9 |
| Male | 13 | 48.1 |
| Age | 27 | 100.0 |
| < 12 months | 9 | 33.3 |
| 12 - 18 months | 3 | 11.1 |
| > 18 months | 15 | 55.6 |
| Stage | 27 | 100.0 |
| 3 | 9 | 33.3 |
| 4 | 18 | 66.7 |
| Site | 27 | 100.0 |
| Right adrenal | 8 | 29.6 |
| Left adrenal | 9 | 33.3 |
| Retropertitoneal | 10 | 37.0 |
| Histology | 27 | 100.0 |
| Unfavorable | 3 | 11.1 |
| Favorable | 7 | 25.9 |
| *Missing | 17 | 63.0 |
| * (diagnosis by bone marrow) | |
| Initial approach | 27 | 100.0 |
| Chemotherapy | 26 | 96.3 |
| Surgery | 1 | 3.8 |
| Surgery (post-chemotherapy) | 26 | 100.0 |
| No | 9 | 34.6 |
| Yes | 17 | 65.4 |
| Surgical Resection | 17 | 100.0 |
| Complete | 10 | 58.8 |
| Incomplete | 7 | 41.2 |
| Complications | 27 | 100.0 |
| No | 16 | 59.3 |
| Yes | 1 | 3.7 |
| No surgery | 10 | 37.0 |
| Status | 27 | 100.0 |
| Alive without disease | 14 | 51.9 |
| Alive with disease (in treatment) | 2 | 7.4 |
| Alive with disease (bone marrow transplantation) | 2 | 7.4 |
| Deceased | 9 | 33.3 |
| Recurrence | 27 | 100.0 |
| No | 22 | 81.5 |
| Yes | 5 | 18.5 |

Resectability was compared between INSS and IDRFS at diagnosis (n=27) and after chemotherapy (n=26). One patient was treated with surgery as initial approach and had complete resection (Table 2).
TABLE 2 – Comparison between INSS and IDRFs

|               | INSS | %     |
|---------------|------|-------|
| Resectable at diagnosis | 27   | 100.0 |
| No            | 26   | 96.3  |
| Yes           | 1    | 3.7   |
| Resectable after chemotherapy | 26   | 100.0 |
| No            | 10   | 38.5  |
| Yes           | 16   | 61.5  |
| IDRFs         | N    | %     |
| Resectable at diagnosis | 27   | 100.0 |
| No            | 23   | 85.2  |
| Yes           | 4    | 14.8  |
| Resectable after chemotherapy | 26   | 100.0 |
| No            | 17   | 65.4  |
| Yes           | 9    | 34.6  |

As for compared resectability between INSS and IDRFs at diagnosis (Kappa=0.362, p=0.007) and after chemotherapy (Kappa=0.354, p=0.019), fragile but significant agreement results were observed. But when comparing results between diagnosis and post-chemotherapy using IDRFs, no agreement was observed (Kappa=0.194, p=0.107). For the INSS criteria it was not possible to calculate Kappa coefficient because all 26 patients were considered unresectable at diagnosis (Figure 1).

FIGURE 1 – Concordance and Kappa values

As for the type of surgical resection at diagnosis and post-chemotherapy, for both INSS and IDRFs there was association for the type of resection post-chemotherapy on IDRF (p=0.001), meaning that all patients considered resectable post-chemotherapy by IDRFs had complete resections. On the other hand, 87.5% of patients considered unresectable had incomplete resections (Table 3).

On the ROC curve, a cut point of 1 on the post-chemotherapy IDRF was associated with 87.5% sensitivity and 66.7% of specificity for incomplete resection. Thus, if all post-chemotherapy patients with one or more IDRFs were classified as incomplete resections, 87.5% would be correctly classified and if classified as complete resections, 66.7% would be correctly classified (Figure 2).

For patients who had surgery after chemotherapy (n=16), differences were observed among number of IDRFs and complete or incomplete resections (p=0.009). The median number of IDRFs was lower for patients that had complete resections.

Survival was impacted by the number of IDRFs. The more IDRFs, the worse was the survival (Figure 3).

FIGURE 2 - ROC curve for complete resections; IDRFs in incomplete resections

FIGURE 3 - Number of IDRFs and survival

77.8% (n=18 patients) are alive and there is similar distribution on stages 3 and 4. Four patients are in treatment, 14 are out of treatment: one had complete response and did
DO THE RADIOLOGICAL CRITERIA WITH THE USE OF RISK FACTORS IMPACT THE FORECASTING OF ABDOMINAL NEUROBLASTIC TUMOR RESECTION IN CHILDREN?

Neuroblastoma is a heterogeneous and multifactorial malignancy and its biology impacts survival rates. Multimodal treatment has enhanced the chances of survival and cure. Literature shows predominance of males, but in the present series, 51.9% of patients were female (p=0.188). Gender had no influence on survival[5,13,17,18]. On the other hand, age at diagnosis of more than 18 months is an independent risk factor for prognosis[14,15]. 55.6% were older than 18 months in this series (mean 30 months), showing the prevalence of high staged tumors.

Concerning site, 62.9% were adrenal, but had no impact on survival (p=0.266).

Surgery is the best initial approach in localized disease, but there is discussion about which is the best to do initially in bigger tumors that encase other structures and advanced staged tumors. The type of surgical resection and staging influence prognosis and some groups advocate complex and risky resections. But others say that aggressive surgery is questionable and has little benefit in high risk patients heavily treated with the multimodal treatment[14,17].

Preoperative chemotherapy is of essence in neuroblastomas that involve renal vessels, celiac trunk or SMA, after which complete resection possibilities can enhance. Nephrectomies should be prevented, when possible[6,14,15].

Mullassery et al did a systematic review on the impact of aggressive surgery in stages 3 and 4 neuroblastomas. Complete resections are associated with better prognosis for stage 3, but have limited impact in stage 4 tumors.

Irtan et al compared images from the diagnosis and preoperatively, with the identification of IDRFs in both moments, along with the site and extent of the tumor and the local impact of chemotherapy for surgery. Resectability was enhanced by chemotherapy when using IDRFs: 14.8% at diagnosis and 34.6% after chemotherapy. In our series, post-chemotherapy IDRFs and the type of surgical resection were convergent since patients classified as resectable in the new criteria were actually resected in the past (p=0.001). For those considered unresectable, 87.5% had incomplete resections.

In a previous study at the same institution in 1998, severe surgical complications occurred in 16.4% with 30.7% mortality[1], but with the advances in chemotherapy, support care and bone marrow transplantation the present series had only one patient with surgical complication and the overall survival that used to be 49.4% is 66.6% today[1].

Of 17 patients with high stage disease treated with surgery, only one post-chemotherapy patient had a surgical complication (hemorrhage). This patient had six IDRFs at diagnosis and two IDRFs after chemotherapy, which correlates to challenges in surgery and incomplete resection, which he had.

The low incidence of surgical complications described, even in high stage disease, can be explained by the fact that the institution is reference for pediatric cancer in Brazil and also the use of preoperative chemotherapy, which reduces the number of IDRFs.

There have been changes in treatment protocols throughout the years and the relapse rate was 18.5%, lower than related in literature. Survival rates are comparable to those described in the literature (66.6%)[1,14].

There are several limitations in this study; it represents casuistic of a single institution; is retrospective; has a limited number of cases; and the biology of the tumor was not analyzed. Further prospective studies should be conducted to better compare INSS with INRGSS.

CONCLUSION

Resectability was similar using INSS and IDRFs systems at diagnosis and post-chemotherapy. Chemotherapy enhances the resectability (14.8–34.6%) for the numbers if IDRFs decline. The presence of at least one IDRF was associated with incomplete resections and there was only one surgical complication and low relapse rate.

REFERENCES

1. ABIB, S. C. V.; SCHETTINI, Sérgio Tomaz. Papel da cirurgia em el tratamento do neuroblastoma. Revista de Cirurgia Infantil, v. 9, p. 197-204, 1999.
2. Brisse JH.; McCarville BM.; Granada C.; Krug BK.; Woothon-Gorges LS.; Kanegawa K.; Glammarie F.; Schimid M.; Shulkin LB.; Matthay KK.; Lewigton JV.; Sarnacki S.; Hero B.; Kaneko M.; London BW.; Pearson IDA.; Cohn LS.; Monclair T. Guidelines for imaging and staging of Neuroblastoma risk group project. Radiology: volume 261: number 1-Oct 2011.Radiology.rsna.org.
3. Canevaro M. Neuroblastoma em crianças: análise de 32 casos [TCC]. Florianópolis: Universidade Federal de Santa Catarina, 2008. https://repositorio.ufsc.br/bitstream/handle/123456789/114977/263014.pdf?
4. Cartum J. Variáveis de prognóstico em crianças maiores de um ano portadoras de neuroblastoma disseminado [tese]. São Paulo: Universidade de São Paulo: 2010. www.teses.usp.br/teses/ disponíveis/s/5/5141/td-18022011-152029/.../JairoCartum.pdf
5. Cecchetto G, Mosseri V., De Bernardi B., Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastomas: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. Journal of Clinical Oncology, 2005;23(33), 8483-8489.
6. Cohn SL., Pearson ADJ., London WB., Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. Journal of Clinical Oncology, 2005;23(33), 8483-8489.
7. Colon CN.; Chung HD. Neuroblastoma. Advances in pediatrics. 2011; 58: 297-311.
8. Davidoff MA. Neuroblastoma. Seminars in Pediatrics Surgery. 2012; 21: 2-14.
9. Irtan S, Brisse HJ., Minard-Colin V., Schleiermacher G., Galmiche-Roland L, Le Cossec C., et al. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection. Pediatr Blood Cancer. 2015: 62:1543-1549.
10. Kembhavi SA., Shah S., Rangarajan V., Qureshi S., Popat P., Kukure P. Imaging in neuroblastoma: An update. The Indian journal of radiology & imaging, 2015; 25(2), 129.
11. Kubota M. The role of surgery in the treatment of Neuroblastoma. Surg. Today. 2010; 40: 526-532.
12. La Quaglia MP., Kushner BH., Su W., Heller G., Kramer K., Abramson S., Rosen N., Wolden S., Cheung NKV. The impact of gross total resection on local control and survival in high-risk neuroblastoma. Journal of pediatric surgery, 2004; 39(3), 412-417.
13. Monclair T., Brodeur GM., Ambros PF., Brisse HJ., Cecchetto G., Holmes K. et al. The international Neuroblastoma risk group (INRG) classification system: An INRG task force report. J Clin Oncol. 2009; 27: number 2-Jan289-297.
14. Colon CN.; Chung HD. Neuroblastoma. Advances in pediatrics. 2011; 58: 297-311.
15. Monclair T., Mosseri V., Cecchetto G., De Bernardi B., Michon J, Holmes K. Influence of image-defined risk factors on the outcome of patients with localised Neuroblastoma. A Report from the LNESG1 study of the European international society of pediatric oncology Neuroblastoma group. Pediatr Blood Cancer. 2015; 62:1536-1542.

ABCD Arq Bras Cir Dig 2017;30(2):88-92
15. Mullassy D., Farrelly P., Losty PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. Pediatric hematology and oncology, 2014; 31:703-716.

16. Rich SB.; McEvoy PM.; Kelly EN.; Oh E.; Abramson JS.; Price PA.; Chung V. K-N.; La Quaglia PM. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. Journal of Pediatric Surgery. 2011; 46:103-107.

17. Siegel MJ., Jaju A. MR Imaging of neuroblastoma masses. Magn Reson Imaging Clin N Am 2008; 16:499-513.